Adhaere Pharmaceuticals, Inc. Adhaere Pharmaceuticals, Inc.
Developing Novel Therapeutics Against Inflammation
Technology
Adhaere has developed an innovative approach for targeting extracellular adhesion receptors on leukocytes for the discovery and development of novel anti-inflammatory drugs. Adhaere's discovery platform technology uses a unique and novel cell-adhesion based high-throughput screening assay for rapid identification and optimization of novel therapeutics and agents against a majority of cell adhesion receptors.
News and Publications

Small molecule mediated activation of integrin CD11b/CD18 reduces inflammatory disease.

Science Signaling, 2011.

view more...